tfeb介导的自噬在胃癌耐药中的作用及其机制研究

《tfeb介导的自噬在胃癌耐药中的作用及其机制研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、分类号R735.2UDC616-006密级公开TFEB介导的自噬在胃癌耐药中的作用及其机制研究蔡习强培养类别全日制学位类型学术学位一级学科(专业类)临床医学二级学科(专业)内科学（消化系病）研究方向胃癌耐药指导教师樊代明教授（主任医师）培养单位西京医院消化病医院二O一五年五月第四军医大学博士学位论文目录缩略语表·······························································································1中文摘要············································

2、···················································3ABSTRACT···························································································7前言······························································································12文献回顾··············································

3、················································14正文······························································································27第一部分自噬是胃癌细胞在化疗药物情况下的重要存活机制························271材料····························································································272方法

4、····························································································283结果····························································································344讨论····························································································40第二部分MTORC1/T

5、FEB信号通路是化疗药物诱导自噬的关键通路···············431材料····························································································432方法····························································································443结果·································································

6、···························474讨论····························································································52第三部分TFEB通过调控LAMP1介导的溶酶体功能和自噬发生，促进胃癌耐药541材料····························································································542方法···································

7、·························································553结果····························································································594讨论·········································